{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:39Z","timestamp":1792123659548,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,10]]},"DOI":"10.7759\/cureus.66611","type":"journal-article","created":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T06:06:47Z","timestamp":1723356407000},"source":"Crossref","is-referenced-by-count":3,"title":["Clinical Patterns and Factors Contributing to Ophthalmic and Otologic Events Associated With Immune Checkpoint Inhibitors: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Amal M","family":"Sunyur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duaa","family":"Alkhayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam A","family":"Alahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layan A","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria Y","family":"Khawaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad S","family":"Badawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: basics and challenges","volume":"26","author":"Li B","year":"2019","unstructured":"Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019, 26:3009-25. 10.2174\/0929867324666170804143706","journal-title":"Curr Med Chem"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon KM","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018, 62:29-39. 10.1016\/j.intimp.2018.06.001","journal-title":"Int Immunopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Tan S","year":"2022","unstructured":"Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2022, 4:579-97. 10.1016\/j.jaccao.2022.09.004","journal-title":"JACC CardioOncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040575","article-title":"Management of the adverse effects of immune checkpoint inhibitors","volume":"8","author":"Morgado M","year":"2020","unstructured":"Morgado M, Pl\u00e1cido A, Morgado S, Roque F. Management of the adverse effects of immune checkpoint inhibitors. Vaccines (Basel). 2020, 8:10.3390\/vaccines8040575","journal-title":"Vaccines (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001675","article-title":"Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma","volume":"8","author":"Rosner S","year":"2020","unstructured":"Rosner S, Agrawal Y, Sun DQ, Aygun N, Schollenberger MD, Lipson E, Naidoo J. Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. J Immunother Cancer. 2020, 8:10.1136\/jitc-2020-001675","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/meajo.MEAJO_256_18","article-title":"Impact of visual impairment and blindness on quality of life of patients in Owerri, Imo State, Nigeria","volume":"26","author":"Ejiakor I","year":"2019","unstructured":"Ejiakor I, Achigbu E, Onyia O, Edema O, Florence UN. Impact of visual impairment and blindness on quality of life of patients in Owerri, Imo State, Nigeria. Middle East Afr J Ophthalmol. 2019, 26:127-32. 10.4103\/meajo.MEAJO_256_18","journal-title":"Middle East Afr J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/43.5.661","article-title":"The impact of hearing loss on quality of life in older adults","volume":"43","author":"Dalton DS","year":"2003","unstructured":"Dalton DS, Cruickshanks KJ, Klein BE, Klein R, Wiley TL, Nondahl DM. The impact of hearing loss on quality of life in older adults. Gerontologist. 2003, 43:661-8. 10.1093\/geront\/43.5.661","journal-title":"Gerontologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman O","year":"2017","unstructured":"Abdel-Rahman O, Oweira H, Petrausch U, et al.. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017, 17:387-94. 10.1080\/14737140.2017.1296765","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1577978","article-title":"Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition","volume":"28","author":"Sun MM MD","year":"2020","unstructured":"Sun MM MD, PhD, Levinson RD MD, Filipowicz A DO, et al.. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm. 2020, 28:217-27. 10.1080\/09273948.2019.1577978","journal-title":"Ocul Immunol Inflamm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun MM","year":"2021","unstructured":"Sun MM, Kelly SP, Mylavarapu Bs AL, et al.. Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology. 2021, 128:910-9. 10.1016\/j.ophtha.2020.11.001","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2014.1001858","article-title":"Ipilimumab-induced ocular and orbital inflammation\u2014a case series and review of the literature","volume":"24","author":"Papavasileiou E","year":"2016","unstructured":"Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM. Ipilimumab-induced ocular and orbital inflammation\u2014a case series and review of the literature. Ocul Immunol Inflamm. 2016, 24:140-6. 10.3109\/09273948.2014.1001858","journal-title":"Ocul Immunol Inflamm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.01.031","article-title":"Ophthalmic immune-related adverse events of immunotherapy: a single-site case series","volume":"126","author":"Kim JM","year":"2019","unstructured":"Kim JM, Materin MA, Sznol M, et al.. Ophthalmic immune-related adverse events of immunotherapy: a single-site case series. Ophthalmology. 2019, 126:1058-62. 10.1016\/j.ophtha.2019.01.031","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2021-000889","article-title":"Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review","volume":"7","author":"Heng JS","year":"2022","unstructured":"Heng JS, Kim JM, Jones DK, et al.. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. BMJ Open Ophthalmol. 2022, 7:e000889. 10.1136\/bmjophth-2021-000889","journal-title":"BMJ Open Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02635-3","article-title":"Factors associated with ocular adverse event after immune checkpoint inhibitor treatment","volume":"69","author":"Kim YJ","year":"2020","unstructured":"Kim YJ, Lee JS, Lee J, Lee SC, Kim TI, Byeon SH, Lee CS. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunol Immunother. 2020, 69:2441-52. 10.1007\/s00262-020-02635-3","journal-title":"Cancer Immunol Immunother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review","volume":"12","author":"Yu CW","year":"2020","unstructured":"Yu CW, Yau M, Mezey N, Joarder I, Micieli JA. Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review. Eye Brain. 2020, 12:139-67. 10.2147\/EB.S277760","journal-title":"Eye Brain"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-22-14","article-title":"Highlights on ocular toxicity of immune checkpoint inhibitors at a US tertiary cancer center","volume":"5","author":"Mazharuddin AA","year":"2022","unstructured":"Mazharuddin AA, Whyte AT, Gombos DS, Patel N, Razmandi A, Chaudhry AL, Al-Zubidi NS. Highlights on ocular toxicity of immune checkpoint inhibitors at a US tertiary cancer center. J Immunother Precis Oncol. 2022, 5:98-104. 10.36401\/JIPO-22-14","journal-title":"J Immunother Precis Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens A","year":"2023","unstructured":"Martens A, Schauwvlieghe PP, Madoe A, Casteels I, Aspeslagh S. Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. J Ophthalmic Inflamm Infect. 2023, 13:5. 10.1186\/s12348-022-00321-2","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref18","unstructured":"EyeWiki. Ocular and orbital complications of checkpoint inhibitors. (2024). Accessed: April 10, 2024: https:\/\/eyewiki.aao.org\/Ocular_and_Orbital_Complications_of_Checkpoint_Inhibitors."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2022.04.19","article-title":"Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management","volume":"15","author":"Zhou YW","year":"2022","unstructured":"Zhou YW, Xu Q, Wang Y, Xia RL, Liu JY, Ma XL. Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management. Int J Ophthalmol. 2022, 15:646-56. 10.18240\/ijo.2022.04.19","journal-title":"Int J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and clinical patterns of ocular complications associated with anti-PD-1\/PD-L1 anticancer immunotherapy","volume":"202","author":"Bitton K","year":"2019","unstructured":"Bitton K, Michot JM, Barreau E, et al.. Prevalence and clinical patterns of ocular complications associated with anti-PD-1\/PD-L1 anticancer immunotherapy. Am J Ophthalmol. 2019, 202:109-17. 10.1016\/j.ajo.2019.02.012","journal-title":"Am J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin LA","year":"2018","unstructured":"Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018, 38:1063-78. 10.1097\/IAE.0000000000002181","journal-title":"Retina"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-41008-7_17","article-title":"Immune-related oral, otologic, and ocular adverse events","volume":"1244","author":"Srivastava A","year":"2020","unstructured":"Srivastava A, Al-Zubidi N, Appelbaum E, Gombos DS, Nader ME, Gidley PW, Chambers MS. Immune-related oral, otologic, and ocular adverse events. Adv Exp Med Biol. 2020, 1244:295-307. 10.1007\/978-3-030-41008-7_17","journal-title":"Adv Exp Med Biol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"Young L","year":"2021","unstructured":"Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, Sharon E. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer. 2021, 9:10.1136\/jitc-2020-002119","journal-title":"J Immunother Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001148","article-title":"Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade","volume":"41","author":"Sun MM","year":"2021","unstructured":"Sun MM, Seleme N, Chen JJ, et al.. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade. J Neuroophthalmol. 2021, 41:519-30. 10.1097\/WNO.0000000000001148","journal-title":"J Neuroophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience","volume":"105","author":"Fortes BH","year":"2021","unstructured":"Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol. 2021, 105:1263-71. 10.1136\/bjophthalmol-2020-316970","journal-title":"Br J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular adverse events induced by immune checkpoint inhibitors: A comprehensive pharmacovigilance analysis","volume":"30","author":"Bomze D","year":"2022","unstructured":"Bomze D, Meirson T, Hasan Ali O, Goldman A, Flatz L, Habot-Wilner Z. Ocular adverse events induced by immune checkpoint inhibitors: A comprehensive pharmacovigilance analysis. Ocul Immunol Inflamm. 2022, 30:191-7. 10.1080\/09273948.2020.1773867","journal-title":"Ocul Immunol Inflamm"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz MZ","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, et al.. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021, 40:949-82. 10.1007\/s10555-021-09976-0","journal-title":"Cancer Metastasis Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.022","article-title":"Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series","volume":"117","author":"Lemasson J","year":"2019","unstructured":"Lemasson J, Cuzzubbo S, Doucet L, et al.. Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series. Eur J Cancer. 2019, 117:116-8. 10.1016\/j.ejca.2019.05.022","journal-title":"Eur J Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26455","article-title":"Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab","volume":"42","author":"Choi JS","year":"2020","unstructured":"Choi JS, Chen M, McQuade JL, Appelbaum E, Gidley PW, Nader ME. Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab. Head Neck. 2020, 42:E35-42. 10.1002\/hed.26455","journal-title":"Head Neck"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/14670100.2023.2193918","article-title":"Bilateral cochlear implantation after immunotherapy-related profound hearing loss: A case report","volume":"24","author":"Schlacter JA","year":"2023","unstructured":"Schlacter JA, Kay-Rivest E, McMenomey SO, Roland JT Jr, Friedmann DR, Jethanamest D. Bilateral cochlear implantation after immunotherapy-related profound hearing loss: A case report. Cochlear Implants Int. 2023, 24:268-72. 10.1080\/14670100.2023.2193918","journal-title":"Cochlear Implants Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-21-17","article-title":"Audiovestibular toxicity secondary to immunotherapy: Case series and literature review","volume":"5","author":"Page JC","year":"2022","unstructured":"Page JC, Gidley PW, Nader ME. Audiovestibular toxicity secondary to immunotherapy: Case series and literature review. J Immunother Precis Oncol. 2022, 5:2-6. 10.36401\/JIPO-21-17","journal-title":"J Immunother Precis Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0120","article-title":"Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019","volume":"12","author":"Hu F","year":"2020","unstructured":"Hu F, Ye X, Zhai Y, et al.. Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019. Immunotherapy. 2020, 12:531-40. 10.2217\/imt-2019-0120","journal-title":"Immunotherapy"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/0145561320940847","article-title":"Bilateral sensorineural hearing loss associated with nivolumab therapy for stage IV malignant melanoma","volume":"100","author":"Tampio AJ","year":"2021","unstructured":"Tampio AJ, Dhanireddy S, Sivapiragasam A, Nicholas BD. Bilateral sensorineural hearing loss associated with nivolumab therapy for stage IV malignant melanoma. Ear Nose Throat J. 2021, 100:286S-91S. 10.1177\/0145561320940847","journal-title":"Ear Nose Throat J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig A","year":"2021","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B, et al.. Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology. 2021, 96:e866-75. 10.1212\/WNL.0000000000011340","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.2.11","article-title":"PD-1\/PD-L1 inhibitors for non-small cell lung cancer: Incorporating care step pathways for effective side-effect management","volume":"10","author":"Davies MJ","year":"2019","unstructured":"Davies MJ. PD-1\/PD-L1 inhibitors for non-small cell lung cancer: Incorporating care step pathways for effective side-effect management. J Adv Pract Oncol. 2019, 10:21-35. 10.6004\/jadpro.2019.10.2.11","journal-title":"J Adv Pract Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1227049","article-title":"Neurological adverse events associated with PD-1\/PD-L1 immune checkpoint inhibitors","volume":"17","author":"Zhou Y","year":"2023","unstructured":"Zhou Y, Li H. Neurological adverse events associated with PD-1\/PD-L1 immune checkpoint inhibitors. Front Neurosci. 2023, 17:1227049. 10.3389\/fnins.2023.1227049","journal-title":"Front Neurosci"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4819-2","article-title":"Efficacy of anti-PD-1\/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)","volume":"18","author":"Tachihara M","year":"2018","unstructured":"Tachihara M, Negoro S, Inoue T, et al.. Efficacy of anti-PD-1\/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer. 2018, 18:946. 10.1186\/s12885-018-4819-2","journal-title":"BMC Cancer"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni A","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022, 13:779691. 10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08083-w","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data","volume":"31","author":"Guven DC","year":"2023","unstructured":"Guven DC, Erul E, Kaygusuz Y, Akagunduz B, Kilickap S, De Luca R, Rizzo A. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023, 31:624. 10.1007\/s00520-023-08083-w","journal-title":"Support Care Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.5152\/iao.2020.7123","article-title":"Evaluation of nivolumab for ototoxic effects: an animal study in rats","volume":"16","author":"G\u00fcler \u0130","year":"2020","unstructured":"G\u00fcler \u0130, Kuzucu \u0130, Baklac\u0131 D, Kum RO, \u00d6zhamam U\u00e7ary\u0131lmaz E, \u00d6zcan M. Evaluation of nivolumab for ototoxic effects: an animal study in rats. J Int Adv Otol. 2020, 16:218-21. 10.5152\/iao.2020.7123","journal-title":"J Int Adv Otol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/282419-clinical-patterns-and-factors-contributing-to-ophthalmic-and-otologic-events-associated-with-immune-checkpoint-inhibitors-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T06:06:51Z","timestamp":1723356411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/282419-clinical-patterns-and-factors-contributing-to-ophthalmic-and-otologic-events-associated-with-immune-checkpoint-inhibitors-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.66611","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,10]]}}}